Information Provided By: 
Fly News Breaks for February 22, 2019
MNKD
Feb 22, 2019 | 09:04 EDT
SVB Leerink analyst Pasha Sarraf initiated MannKind with an Outperform rating and $3 price target, telling investors in a research note that this is a "do or die" year for the company. Sarraf says he is positive on the immunology sector with its diverse indications, continuous innovation, and deep expertise, and is looking long for opportunities in challenging immuno-metabolism and metabolism sectors, in areas like NASH, obesity and diabetes.
News For MNKD From the Last 2 Days
There are no results for your query MNKD
